22 February, 2017

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq: FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain. A link to Mike’s interview can be found below:

http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases

F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis

Germany’s top research institutions and venture capital investors unite behind spin-off framework

Sofinnova Partners launches collaboration with AWS to scale AI across life sciences innovation

Moon Surgical expands Maestro® platform into a multi-model physical AI platform with software Version 2.7

Ingenix raises €13M led by Sofinnova to scale Modality Fusion AI